NCT Number: NCT00139698
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Looking for future studies?
Notify MeKey information
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Pfizer Investigational Site, Medellín, Antioquia, Colombia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject has mild to moderate hypertension
Exclusion criteria
- History of secondary hypertension
Treatment and study plan
Primary outcomes
-
Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Secondary outcomes
-
Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Acronym: OSCAR
Important dates
- Study start
- 2005
- Study completion
- 2006
- First posted
- Aug 31, 2005
- Registry last updated
- Dec 5, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
NCT06416865
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial DetailsPhase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
NCT05503953
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial DetailsEvaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
NCT05573477
Cardiovascular Diseases, Diabetes Mellitus
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsA Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
NCT06165250
Cardiovascular Diseases, Essential Hypertension
Daegu, South Korea
View Trial Details